Press release
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,
About this update from Castle Biosciences, Inc.
[{"type":"text","content":" FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6. DecisionDx-Melanoma is the Company’s genomic risk-stratification test for patients with cutaneous melanoma, and DecisionDx-UM is the standard of care in the management of newly diagnosed uveal melanoma in the majority of ocular oncology practices in the United States.\n\n\nDetails regarding Castle’s accepted abstracts are as follows:\n\n\nDecisionDx-Melanoma\nAbstract #6601: Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.\nFirst Author: David Hyams, M.D., F.A.C.S., director of Desert Surgical Oncology in Rancho Mirage, California\nSession Type: Poster Session\nPoster Bd #: 93\nSession Title: Health Services Research and Quality Improvement\nDate & Time: Saturday, June 3, 1:15-4:15 p.m. Central time\n\n\nThe abstract can be viewed here.\n\n\nDecisionDx-UM\nAbstract #e21574: Long-term outcomes in a population-based cohort of 2,967 uveal melanoma patients clinically tested with the 15-gene expression profile: A collaborative study with the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Registries.\nSession Type: Publication Only\nSession Title: Publication Only: Melanoma/Skin Cancers\n\n\nThe abstract can be viewed here.\n\n\nAbout DecisionDx-Melanoma\n\n\nDecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient s...